Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up ... different class of drugs than Novo Nordisk's blockbuster diabetes and weight-loss treatments Ozempic and Wegovy. Novo Nordisk is busy ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Parvus Asset Management is building a stake in Novo Nordisk and hopes to influence its choice of a new CEO. Novo Nordisk ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...